Mallett RW[au] - Search Results

Year	Number of Results
2000	1
2001	1
2002	3
2003	1
2004	1
2024	0

1

Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.

Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Theodore LJ, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW, Carrasquillo JA. Yao Z, et al. Among authors: mallett rw. Clin Cancer Res. 2004 May 1;10(9):3137-46. doi: 10.1158/1078-0432.ccr-03-0171. Clin Cancer Res. 2004. PMID: 15131055

2

Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F, Hobson LJ, Beaumier PL, Fritzberg AR. Axworthy DB, et al. Among authors: mallett rw. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1802-7. doi: 10.1073/pnas.97.4.1802. Proc Natl Acad Sci U S A. 2000. PMID: 10677537 Free PMC article.

3

Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213.

Zhang M, Yao Z, Garmestani K, Axworthy DB, Zhang Z, Mallett RW, Theodore LJ, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA. Zhang M, et al. Among authors: mallett rw. Blood. 2002 Jul 1;100(1):208-16. doi: 10.1182/blood-2002-01-0107. Blood. 2002. PMID: 12070029 Free article.

4

Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.

Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, Mallett RW, Theodore LJ, Stayton PS, Press OW. Subbiah K, et al. Among authors: mallett rw. J Nucl Med. 2003 Mar;44(3):437-45. J Nucl Med. 2003. PMID: 12621012 Free article.

5

A robust method for the preparation and purification of antibody/streptavidin conjugates.

Hylarides MD, Mallett RW, Meyer DL. Hylarides MD, et al. Among authors: mallett rw. Bioconjug Chem. 2001 May-Jun;12(3):421-7. doi: 10.1021/bc0001286. Bioconjug Chem. 2001. PMID: 11353541

6

Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin.

Wilbur DS, Hamlin DK, Meyer DL, Mallett RW, Quinn J, Vessella RL, Press OW. Wilbur DS, et al. Among authors: mallett rw. Bioconjug Chem. 2002 May-Jun;13(3):611-20. doi: 10.1021/bc015574n. Bioconjug Chem. 2002. PMID: 12009953

7

Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.

Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA. Yao Z, et al. Among authors: mallett rw. Cancer Res. 2002 Oct 15;62(20):5755-60. Cancer Res. 2002. PMID: 12384535

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

7 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year